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There is a pressing need for new antimicrobial therapies to combat globally important drug-resistant human pathogens, includ-
ing Plasmodium falciparummalarial parasites,Mycobacterium tuberculosis, and Gram-negative bacteria, including Escherichia
coli. These organisms all possess the essential methylerythritol phosphate (MEP) pathway of isoprenoid biosynthesis, which is
not found in humans. The first dedicated enzyme of the MEP pathway, 1-deoxy-D-xylulose 5-phosphate reductoisomerase (Dxr),
is inhibited by the phosphonic acid antibiotic fosmidomycin and its analogs, including theN-acetyl analog FR900098 and the
phosphoryl analog fosfoxacin. In order to identify mutations in dxr that confer resistance to these drugs, a library of E. coli dxr
mutants was screened at lethal fosmidomycin doses. The most resistant allele (with the S222Tmutation) alters the fosmidomy-
cin-binding site of Dxr. The expression of this resistant allele increases bacterial resistance to fosmidomycin and other fosmido-
mycin analogs by 10-fold. These observations confirm that the primary cellular target of fosmidomycin is Dxr. Furthermore, cell
lines expressing Dxr-S222T will be a powerful tool to confirm the mechanisms of action of future fosmidomycin analogs.
Isoprenoids represent the most diverse class of natural productsand are essential to all living cells (1, 2). Notable isoprenoids
include such critical molecules as chlorophyll, ubiquinone, and
cholesterol. All isoprenoids are derived from a common set of
precursors, the 5-carbon molecules isopentenyl pyrophosphate
(IPP) and its isomer dimethylallyl pyrophosphate (DMAPP) (3).
Both IPP and DMAPP are synthesized de novo by all free-living
organisms, and a failure to produce these compounds is incom-
patible with life. Most eukaryotes, including humans, utilize the
six-step mevalonate (MVA) pathway, which produces IPP and
DMAPP from acetyl-coenzyme A (CoA) (4). In contrast, an alter-
native independently evolved route, the 2-C-methyl-D-erythritol
4-phosphate (MEP) pathway, is utilized by Gram-negative bacte-
ria, a subset of Gram-positive bacteria, plastid-containing eu-
karyotes, including parasitic protozoa in the Apicomplexa phy-
lum, and plants (which additionally use the MVA pathway in the
cytoplasm) (4, 5). Unlike the MVA pathway, the MEP pathway
utilizes pyruvate and glyceraldehyde 3-phosphate in a seven-step
enzymatic cascade to produce IPP and DMAPP (6, 7) (Fig. 1A).
The MEP pathway is essential in key human pathogens, including
Plasmodium falciparum malarial parasites and the bacterium My-
cobacterium tuberculosis, and in many Gram-negative bacterial
pathogens (8–11). Because this pathway is absent in humans, MEP
pathway enzymes represent an attractive target for antimicrobial
development (12, 13).
To date, the most successful antimicrobial agents targeting
the MEP pathway are the phosphonic acid fosmidomycin
(FSM) and its N-acetyl and phosphoryl analogs, FR900098 and
fosfoxacin (Fig. 1B). FSM and its analogs inhibit the growth of
a wide range of organisms that utilize the MEP pathway, in-
cluding P. falciparum, bacteria, and plants (8, 14–17). Of these,
FSM has been investigated most extensively. Enzymatic analysis
has shown that FSM potently inhibits the first dedicated step of the
MEP pathway, the reduction/isomerization of 1-deoxy-D-xylu-
lose 5-phosphate (DOXP) to MEP by the enzyme DOXP reduc-
toisomerase (Dxr) (EC 1.1.1.267) (18). FSM appears to act as a
slow tight-binding inhibitor that binds within the active site in
competition with the DOXP substrate (19). However, in vivo anal-
ysis has shown that the subsequent step in the pathway, the cyt-
idylation of MEP by the enzyme MEP cytidyltransferase (IspD),
may be a secondary target of FSM (20).
Initial clinical studies have demonstrated that fosmidomy-
cin is safe and moderately effective in the treatment of clinical
malaria (21, 22); the drug is currently in phase IIb studies in
combination with piperaquine (23). FSM has several limita-
tions as a clinical therapeutic. Its highly charged nature results
in poor pharmacokinetics and a plasma half-life of 3.5 h (24,
25). In addition, there is an unacceptably high rate of recrudes-
cent malaria in children treated with the FSM combinations
tested so far, likely related to this rapid plasma clearance (25,
26). Finally, FSM is excluded from most cells, with the excep-
tion of organisms, such as P. falciparum and Escherichia coli,
which actively transport this compound (27, 28). Because of this
impermeability, FSM is ineffective against many potential patho-
gens, such as Toxoplasma gondii (29) and M. tuberculosis (10).
Thus, substantial efforts have been made to develop more cell-
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permeable analogs of FSM or its highly related analog, FR900098
(30–35).
A wealth of enzymatic, crystallographic, and clinical data have
been collected in the study of FSM and its Dxr target (19, 24,
36–38), yet no mutation in dxr has been reported to confer resis-
tance to FSM. Targeted mutagenesis studies have identified resi-
dues in Dxr that affect enzymatic activity (39, 40), yet some of
these variant Dxr enzymes bind FSM even when enzymatic activ-
ity has been abolished. In the current study, we took a targeted
mutagenic approach to identify FSM-interacting residues. We
used error-prone PCR to screen for possible sequence changes in
dxr and ispD that confer resistance in E. coli to FSM. Using this
approach, we demonstrated that mutations in dxr can confer re-
sistance to FSM in vivo and in vitro, and we characterized the
enzymologic effects of FSM-resistant dxrmutant proteins. Finally,
we established the utility of a FSM-resistant E. coli strain for vali-
dating the mechanism of antimicrobial activity of a novel
FR900098 prodrug. Our results demonstrate that FSM-resistantE.
coli will be a valuable tool in screening efforts to identify novel
inhibitors targeting the Dxr active site and for confirming the
mechanisms of action of rationally designed fosmidomycin and
FR900098 analogs.
MATERIALS AND METHODS
Generation ofmutant libraries ofE. coli dxr and ispD.A library contain-
ing a collection of either dxr mutants or ispD mutants was created using a
modified protocol for error-prone PCR (41). The reaction buffer included
10 mM Tris (pH 8.3), 50 mM KCl, 4 mM MgCl2, 0.2 mM dATP, 0.2 mM
dGTP, 2 mM dCTP, 2 mM dTTP, 400 M forward primer, 400 M
reverse primer, 20 pg/l template DNA, and 0.05 U/l Taq DNA poly-
merase (Sigma-Aldrich) in a final reaction volume of 50 l. The forward
primer used for dxr amplification was 5=-GGGGACAAGTTTGT
ACAAAAAAGCAGGCTGCATGAAGCAACTCACCATTCTGGG-
3=, and the primer for ispD amplification was 5=-GGGGACAAGTTT
GTACAAAAAAGCAGGCTGCATGGCAACCACTCATTTGGATG-
3=. The reverse primer used for dxr amplification was 5=-GGGGAC
CACTTTGTACAAGAAAGCTGGGTTCAGCTTGCGAGACGCATCA
CCTCT-3=, and the primer for ispD amplification was 5=-GGGGACC
ACTTTGTACAAGAAAGCTGGGTTTATGTATTCTCCTGATGGAT
GGTTCG-3=. PCR products were then cloned into the vector pDONR221
using the Gateway BP reaction (Invitrogen), which was used to transform
chemically competentE. coli strain TOP10 cells (Invitrogen), and colonies
containing library DNA were selected for on LB agar plates containing 50
g/ml kanamycin (Sigma-Aldrich). Each transformation yielded approx-
imately 10,000 individual colonies, which were scraped off the plates and
pooled in LB liquid medium just prior to DNA purification. The plasmid
libraries were then used to insert either the ispD or dxr gene into the
bacterial expression vector pDX-ccdB using the Gateway LR reaction (In-
vitrogen) to yield many pDX-ispD and pDX-dxr variants. Construction of
the pDX-ccdB vector proceeded as follows: the genomic dxr sequence
from E. coli strain K-12 substrain MG1655, along with flanking regions
assumed to comprise the transcription promoter and terminator, were
previously TOPO cloned into the proprietary vector pCR2.1 (Life Tech-
nologies). In order to create a Gateway destination plasmid, with expres-
sion under the control of the dxr promoter, a 1,531-bp sequence flanked
by the BamHI and EagI sites, and including the entire E. coli-derived
sequence (1,455 bp), was cut out of the pCR2.1-derived vector and in-
serted into pBR322 (New England BioLabs) between the BamHI and EagI
restriction sites. Ninety-eight percent of the dxr coding sequence, located
between the BanII and BbvCi restriction sites, was removed by restriction
enzyme digestion and replaced, via blunt-end ligation cloning, with se-
quence amplified from the proprietary Gateway destination vector
pDEST17 (Life Technologies). This sequence had been amplified using
the forward primer 5=-CAGGATATCACAAGTTTGTACAAAAAAGCT
GAAC-3= and the reverse primer 5=-GCAGCCTCAGCGGTACCACTTT
GTACAAGAAAGCTGAAC-3=. TOP10 chemically competent cells were
transformed with the new expression library and plated on LB agar plates
containing 100g/ml ampicillin (Sigma-Aldrich) (LB/amp plates), yield-
ing approximately 11,000 colonies in the dxr library and 8,000 colonies in
the ispD library. Colonies were scraped off the plates, pooled in medium,
and either frozen in 15% glycerol at80°C or used immediately to screen
for FSM resistance.
Screening of thedxr and ispD libraries. For each library, a total of 6
105 CFU of TOP10 cells (transformed with library pDX-ispD or pDX-dxr)
were plated across six LB/amp plates, three containing 100 M FSM (In-
vitrogen) and three containing 50 M FSM, and grown at 37°C for 18 h.
The resulting colonies were restreaked on plates with LB/amp plus 50M
FSM. The plates were left at ambient temperature, and additional colonies
FIG 1 Mutations in MEP pathway genes confer resistance to fosmidomycin (FSM). (A) FSM inhibits catalysis by Dxr of the conversion of DOXP to MEP, with
concomitant oxidation of NADPH. (B) Structures of inhibitors used in this study. (C) Schematic of selection strategy for ispD or dxr variants that confer
resistance to FSM.
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that formed after another 48 h were also restreaked. After final growth at
37°C for 24 h, a single colony from each plate was grown in liquid LB/amp
medium, and the plasmid was isolated using the QIAprep spin miniprep
kit (Qiagen). Calcium chloride competent MG1655E. coli cells (a kind gift
of David Hunstad, Washington University) were transformed with the
isolated plasmid, and transformants were streaked onto plates with LB/
amp plus 50M FSM. Strains that continued to grow after retransforma-
tion were further analyzed.
Measurement of growth inhibition of E. coli. Growth inhibition of E.
coliwas evaluated as previously described (20). In brief, overnight cultures
of E. coli were diluted 1:100 into fresh LB medium supplemented with
either the appropriate antibiotic or no antibiotic if no plasmid was main-
tained and grown to an optical density at 600 nm (OD600) of 0.5. Cultures
were diluted to 105 CFU/ml in 200 l/well of a 96-well plate, with the
indicated amounts of the inhibitory compound. Bacteria were grown in a
FLUOstar Omega microplate reader (BMG Labtech) at 37°C and 700
rpm, with serial OD600 measurements. The GraphPad Prism software was
used to calculate inhibitory constants (50% effective concentrations
[EC50s]) during logarithmic growth (8 to 10 h). All EC50s in the text reflect
the means from three or more independently performed experiments.
Site-directedmutagenesis of dxr. The vector pCR2.1-dxr was created
by using PCR to amplify the 2,817-bp sequence between nucleotides
192528 and 195344 on the E. coli chromosome, which was then cloned
into the vector pCR2.1 using the TOPO-TA cloning kit (Invitrogen). The
vector pACYC-dxr was created by cloning the 2,911-bp insert between the
HindIII and NotI sites in pCR2.1-dxr and ligating it into the vector
pACYC184 with the 910-bp HindIII/EagI fragment removed. The vector
pACYC-dxr-S222T was created using the QuikChange site-directed mu-
tagenesis kit (Stratagene) and primers with the sequences 5=-CCAGACC
TTTGTTCATCATGGTAGCCGTGTCGACAGAAATTTTACGCCCCA
TCG-3= and 5=-CGATGGGGCGTAAAATTTCTGTCGACACGGCTAC
CATGATGAACAAAGGTCTGG-3=, which alter nucleotides at positions
663 and 664 in the open reading frame (ORF) from TT to CA. This mu-
tation changes the codon for serine 222 to a threonine and creates a novel
AccI restriction cleavage site at positions 658 to 663. Site-directed mu-
tagenesis was confirmed by successful digestion with AccI and Sanger
sequencing.
Purification of recombinant Dxr. Either wild-type dxr or dxr-S222T
was cloned into the vector BG1861 using ligation-independent cloning
(42), and recombinant protein was purified as previously described, with
some minor modifications (20). Cells were lysed in lysis buffer (25 mM
Tris [pH 7.5], 250 mM NaCl, 1 mM MgCl2, 0.1% Triton X-100, 5 mM
dithiothreitol [DTT], 20 mM imidazole, 1 mg/ml lysozyme, 200 M
phenylmethylsulfonyl fluoride [PMSF], EDTA-free cOmplete Protease
Inhibitor Tablets [Roche]) and then sonicated to complete lysis and shear
DNA. Protein was purified over nickel agarose beads (Gold Biotechnol-
ogy) and then further purified over a HiLoad 16/60 Superdex 200 (GE Life
Sciences) size exclusion column, and fractions were collected using an
ÄKTAexplorer 100 air fast protein liquid chromatography (FPLC) (GE
Life Sciences). Fractions containing the recombinant protein were subse-
quently combined and concentrated using Amicon Ultra-15 10,000-nom-
inal molecular weight limit (NMWL) centrifugal filters (Millipore). Final
protein concentrations were obtained using a bicinchoninic acid (BCA)
protein assay kit (Thermo Scientific Pierce).
Dxr enzyme activity. Recombinant Dxr enzyme activity was mea-
sured by monitoring the oxidation of NADPH to NADP by tracking the
absorbance at 340 nm in a POLARstar Omega microplate reader (BMG).
Standard reactions were performed in a 50-l volume in reaction buffer
(25 mM Tris [pH 7.5], 100 mM NaCl, 7.5 mM MgCl2, 0.1 mg/ml bovine
serum albumin [BSA]) with 200 M DOXP (Echelon), 400 M NADPH
(Sigma-Aldrich), 50 ng of Dxr, and the appropriate concentration of in-
hibitory compound. The Km[DOXP] was determined at fixed NADPH
concentrations and DOXP concentrations from 0 to 5 mM. The reaction
mixtures were incubated for 15 min at 37°C in the presence of all compo-
nents except for DOXP. The reactions were initiated by adding DOXP,
and NADPH conversion was continuously measured for up to 30 min.
Kinetic parameters were determined by nonlinear regression (GraphPad
Prism). All 50% inhibitory concentration (IC50), Km, Ki, and Vmax values
in the text reflect the means of the results from three or more indepen-
dently performed experiments.
Allelic replacement of the genomicdxr locus.Allelic replacement was
performed with a modified version of the pKO vector system (43). The
vector pKOV-dxrS222T was created by cutting a 2,875-bp BamHI/PstI
fragment from the vector pACYC-dxrS222T and ligating it into pKOV,
after removal of the 2,036-bp BamHI/PstI fragment. The pKOV-
dxrS222T vector was used to transform either E. coli MG1655 or E. coli
BW25113bamBtolC (a kind gift of Gerard Wright, McMaster Univer-
sity, Ontario, Canada) (44). Colonies were grown on LB with either 30
g/ml (for MG1655) or 6 g/ml (for BW25113 bamBtolC) of chlor-
amphenicol at 30°C for 48 to 72 h. Colonies were picked and grown
overnight at 42°C in LB at the appropriate concentration of chloramphen-
icol. Cells were diluted and grown to an OD600 of approximately 0.5, at
which point they were diluted 200- and 2,000-fold. Two hundred micro-
liters of each diluted culture was plated on LB medium supplemented with
5% sucrose and grown at 37°C overnight. A total of eight colonies were
isolated and screened for allelic replacement. This evaluation involved
PCR amplification of the dxr locus from genomic DNA (gDNA), followed
by digestion of the PCR product with the restriction enzyme AccI. An AccI
cut site is present in dxr-S222T but absent from the wild-type allele. Allelic
replacement was validated by Sanger sequencing.
RESULTS
Identification of FSM resistance alleles of dxr but not ispD. In
vitro, FSM inhibits the first dedicated enzyme of the MEP path-
way, deoxyxylulose phosphate reductoisomerase (Dxr), also
known as IspC. Surprisingly, previous metabolic profiling of
FSM-treated cells indicated that the downstream MEP pathway
enzyme IspD (methylerythritol phosphate cytidyltransferase, EC
2.7.7.60) was an unexpected second intracellular target of FSM
(20). Since FSM was not found to inhibit recombinant IspD in
vitro at physiologically relevant concentrations, our previous
studies suggested that the inhibition of IspD was likely indirect.
We evaluated whether amino acid changes in Dxr and/or IspD
might confer FSM resistance in order to confirm which enzyme is
the primary intracellular target and to establish a system for vali-
dating the antimicrobial mechanisms of action of future FSM an-
alogs (Fig. 1C).
To investigate mutations in dxr and ispD that might confer
FSM resistance, we used error-prone PCR to generate expression
libraries of dxr and ispD mutants in the model Gram-negative
bacterium E. coli (see Fig. 1B for experimental scheme). Trans-
formed cells were selected on plates containing lethal concentra-
tions of FSM (50 or 100 M). Based on similar error-prone PCR
protocols (41), the estimated complexity of the dxr library was
104 individual clones. For every 105 CFU plated, an average of
350 colonies were observed, suggesting that 35 separate FSM-re-
sistant dxr mutants were present (0.35% of the library). A total of
48 resistant colonies were restreaked onto FSM-containing me-
dium (100 M), and the seven colonies with the most robust
growth were analyzed further. A comparable number of cells were
transformed with the ispD library. ispD transfectants were not
observed on FSM-containing medium until 2 days of growth, at
which time eight total colonies from the ispD library were evident;
all eight were restreaked onto LB/amp plates containing 100 M
FSM. This suggests a much lower rate of resistant clones
(0.0013%) for the ispD library than that with the dxr library.
To confirm that FSM resistance was plasmid dependent, plas-
Fosmidomycin and Prodrug Resistance in Dxr Gene
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mids were isolated from seven dxr library (pDX-dxr) clones and
all eight ispD library (pDX-ispD) clones. Restriction digest evalu-
ation demonstrated that two of the eight ispD plasmids did not
contain an ispD insert. All plasmids with the proper inserts, along
with both dxr and ispDwild-type controls, were used to transform
the wild-type fosmidomycin-sensitive K-12 derivative E. coli
strain MG1655. These transformants were evaluated for FSM re-
sistance by determination of the half-maximal effective concen-
tration (EC50) at 8 h of growth (mid-logarithmic growth phase),
compared to that of the controls. None of the ispD library trans-
formants demonstrated FSM resistance (see Fig. S1 in the supple-
mental material). In contrast, strains expressing pDX-dxr plas-
mid-borne FSM-resistant dxr alleles demonstrated a 2- to 10-fold
decrease in sensitivity to FSM compared to that with strains ex-
pressing plasmid-borne wild-type dxr (Table 1; see also Fig. S2 in
the supplemental material).
Two mutants in particular, dxr1 and dxr3, showed significantly
increased EC50s of 53 M (95% confidence interval [CI], 40 to 71
M; P 0.0001) and 45 M (95% CI, 37 to 55 M; P 0.0001),
respectively, compared to a control EC50 of 4.4M (95% CI, 3.7 to
5.3 M), and were therefore chosen for additional analysis. The
sequencing of dxr from each vector revealed that dxr1 and dxr3
contained the exact same set of mutations. Five amino acid
changes were encoded by dxr1 and dxr3: N38Y, M68L, T202A,
S222T, and I256F. Of these mutations, site-directed mutagenesis
of an evolutionarily conserved serine-to-threonine (S222T) mu-
tation (Fig. 2A) produced a dxr allele that conferred FSM resis-
tance, similar to that of both the dxr1 and dxr3 variants (Fig. 2B;
see also Fig. S2 in the supplemental material).
Enzymatic analysis of Dxr-S222T protein. The structure of
the E. coli Dxr-FSM complex has been solved and demonstrates
that Ser222 coordinates the phosphonate moiety of the inhibitor
(36–38) (Fig. 2C). Structural modeling suggested that dxr-S222T
confers resistance to FSM by directly reducing the susceptibility of
the target enzyme, Dxr, to inhibition by FSM. We therefore com-
pared the FSM susceptibility of purified recombinant wild-type
Dxr enzyme to that of the Dxr-S222T variant. As expected, the
S222T variant was 30-fold more resistant to FSM than the wild-
type enzyme (IC50, 1,100 nM [95% CI, 598 to 1,840 nM] com-
pared to 34 nM [95% CI, 27 to 41 nM] [t test, P 0.0001] [Table
2 and Fig. 3A]). During these assays, we observed that in the ab-
sence of FSM treatment, mutant enzyme activity was substantially
reduced compared to that of wild-type Dxr. Since FSM is expected
to bind in a manner similar to that of the natural Dxr substrate
DOXP, we therefore evaluated the effect of the S222T variant on
Dxr enzyme kinetics (Fig. 3B). In our hands, the mean	 standard
error of the mean (SEM) Km[DOXP] of wild-type Dxr was 150	
22M, similar to previously reported values (19). In contrast, the
Km[DOXP] of Dxr-S222T was increased 7-fold (mean 	 SEM,
1,000	 140 M; t test, P 0.001; Table 2). The maximum reac-
tion velocity (Vmax) of Dxr-S222T was not significantly different
from that of the wild-type variant (mean	 SEM, 12	 0.3 versus
11	 0.5mol/min/mg; t test, P
 0.31; see Table 2). While Km as
an enzymatic constant is not an exact measurement of substrate
binding, it is typically correlated with substrate-enzyme affinity.
Our data therefore suggest that the S222T mutation causes a de-
creased affinity for DOXP without a change in the reaction rate.
FSM is a slow tightly binding inhibitor that is competitive with
the structurally similar DOXP substrate (19). Since Dxr-S222T is
less sensitive to FSM and appears to have a reduced affinity for
DOXP, it is likely that FSM resistance in Dxr-S222T reflects a
reduced affinity for FSM. TheKi parameter is an approximation of
the binding affinity between an enzyme and its inhibitor. A com-
parison of the Ki values of wild-type Dxr (Fig. 4A) and Dxr-S222T
(Fig. 4B) suggests a 70-fold decrease in affinity for FSM compared
to that of the wild-type Dxr (mean 	 SEM, 11 	 0.6 nM versus
730	 14 nM,P 0.0001; Table 3). The S222T mutation therefore
appears to exert a profound effect on the ability of FSM to interact
with Dxr, and under FSM selection, the benefit conferred by FSM
resistance appears to outweigh any potential defects caused by a
decrease in DOXP affinity.
Allelic exchange of S222T inE. coli strains. The MEP pathway
is essential for growth in bacteria, and Dxr catalyzes a rate-limiting
step in this pathway (45–47). During initial screening and identi-
fication of the FSM-resistant DXR-S222T allele, mutant dxr vari-
C Ser222




E. coli 212 WSMGRKISVDSATMMNKGLEYI
M. tuberculosis 203 WSMGPMNTLNSASLVNKGLEVI
B. subtilis 200 WSMGAKITIDSATMMNKGLEVI
A. thaliana 301 WNMGKKITVDSATLFNKGLEVI
P. vivax 334 WKMGPKITIDSATMMNKGLEVI











FIG 2 Dxr-S222T confers FSM resistance in bacteria. (A) Sequence compar-
ison of Dxr/IspC homologs from multiple organisms, including a Gram-neg-
ative bacterium (E. coli), Gram-positive bacterium (Bacillus subtilis), myco-
bacterium (M. tuberculosis), green plant (Arabidopsis thaliana), and malarial
parasites (Plasmodium vivax and P. falciparum), demonstrates the conserva-
tion of Ser222 (highlighted in yellow). Alignments were produced in Laser-
gene/MegAlign (DNAStar) using the Clustal W algorithm. The NCBI acces-
sion numbers areE. coli, AAC73284.1;B. subtilis, AGG61028.1;M. tuberculosis,
CCE38326.1; A. thaliana, AED97658.1; P. falciparum, AAD03739.1; and P.
vivax, EDL45988.1. (B) FSM sensitivity of E. coli expressing plasmid-borne
(pACYC-dxr) wild-type dxr, compared to E. coli expressing dxr-S222T (pA-
CYC-dxr-S222T). Data points and error bars represent means 	 standard
errors of the mean (SEM). (C) Structure of FSM-bound E. coli Dxr (PBD ID
1Q0L [37]), demonstrating coordination of the phosphonate moiety of FSM
through hydrogen bonding to Ser222.
TABLE 1 EC50s in E. coli upon episomal (pDX-dxr) expression of wild-
type (dxr-wt) or FSM-resistant dxr alleles (dxr1 to -7)a









a Data are from at least three independent experiments.
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ants were expressed episomally, and the native dxr locus was still
present in the genome. We therefore evaluated whether dxr-S222T
alone was sufficient to support the growth of E. coli when the
native dxr gene was disrupted. The pKOV plasmid system (43) was
used to exchange the wild-type allele of dxr with the dxr-S222T
allele (see Fig. S3 in the supplemental material). Compared to the
expression of wild-type dxr, expression of dxr-S222Tdid not cause
a significant change in growth rate in E. coli (Fig. 5A) (doubling
time under these conditions, 56	 2 min for the wild-type strain
versus 58	 3 min for the FSM-resistant strain [t test, P
 0.74]).
These results demonstrate that strains expressing the dxr-S222T
allele grow at a rate comparable to that of the wild-type strains,
despite the 7-fold increase in Km for the Dxr substrate DOXP. As
expected, the dxr-S222T-expressing strain was resistant to FSM,
with an EC504-fold higher (4.1M; 95% CI, 1.6 to 10M) than
that of the strain expressing the wild-type allele (0.93M; 95% CI,
0.70 to 1.2 M; P 0.001; Fig. 5B and Table 4).
Effects of S222T allele on FR900098 prodrug. While FSM has
shown some promise as a potential antimalarial therapeutic, its
hydrophilicity contributes to poor cellular permeability and short
plasma half-life (35). One strategy to improve the efficacy and
pharmacokinetics of FSM and its analogs is to generate neutral
prodrugs in which the negatively charged phosphonyl group is
masked. However, because intracellular activation is required,
these prodrugs cannot be tested directly in vitro for inhibition of
Dxr activity. Since the FSM-resistant strain carrying the dxr-
S222T allele differs from wild-type E. coli by a single amino acid,
we hypothesized that strains with the dxr-S222T allele could be
used in a simple definitive cellular assay to verify the mechanisms
of action of novel FSM analogs, including prodrugs requiring in-
tracellular activation to release a Dxr inhibitor. To demonstrate
the utility of this approach, we evaluated the MG1655-dxr-S222T
strain for resistance to a phosphonamidate prodrug designed to
undergo intracellular activation to release FR900098, a close
structural analog of fosmidomycin (D. J. Meyers, E. Nenortas,
J. M. Smith, C. M. Armstrong, A. R. Odom, T. A. Shapiro, and
C. L. Freel Meyers, unpublished data) (Fig. 1B). FR900098 re-
leased from the prodrug is predicted to bind to Dxr in a manner
similar to that of FSM. We find that the S222T mutation confers
approximately 35-fold enzymatic resistance to FR900098, which
closely mimics the effect of this mutation on FSM inhibition
(IC50s, 24 nM [95% CI, 21 to 29 nM] and 890 nM [95% CI, 560 to
1,400 nM] against wild-type and S222T mutant enzymes, respec-
tively) (Table 4; see also Fig. S4 in the supplemental material).
Initial experiments indicated that the prodrug exerts minimal an-
tibacterial activity against E. coli, making it difficult to interpret its
effect on the mutant strain (Table 4; see also Fig. S5 in the supple-
mental material).
Because many compounds lack efficacy against E. coli as a re-
sult of active cellular export, E. coli strains with selective disrup-
tion of efflux pumps have been developed that demonstrate en-
hanced susceptibility to many compounds (48, 49). Therefore, we
replaced the native dxr locus with dxr-S222T in the efflux-defec-
tive E. coli strain BW25113 bamBtolC (44). In this strain, as in
MG1655, expression of the dxr-S222T allele confers substantial
resistance to FSM (EC50s, 0.37 M [95% CI, 0.22 to 0.64 M]
versus 5.0M [95% CI, 2.4 to 11M] for BW25113bamBtolC
and BW25113 bamBtolC-dxr-S222T, respectively; t test, P 
0.0005) (Fig. 6A). Resistance to FR900098 was also observed
(EC50s, 100M [95% CI, 66 to 150M] versus 570M [95% CI,
270 to 1,200 M] for BW25113 bamBtolC and BW25113
bamBtolC-dxr-S222T, respectively; P  0.001) (Fig. 6B and
Table 4). For the FR900098 prodrug, the strain with the dxr-S222T
allele was 7-fold more resistant than the isogenic parent (EC50s, 67
FIG 3 Purified recombinant Dxr-S222T is resistant to FSM in vitro. (A) FSM
sensitivity of purified recombinant wild-type () and S222T (Œ) Dxr en-
zymes. (B) Activity of purified recombinant Dxr enzymes (wild-type [] and
S222T [Œ]) with increasing concentrations of DOXP substrate, as indicated,
used for determination of kinetic parameters (Table 2). The data shown are
representative of the results of at least three independent experiments. Activity
is measured in micromoles per minute per milligram of enzyme. The data
points and error bars represent mean	 standard error of the mean (SEM). wt,
wild type.
FIG 4 Inhibitory kinetics of wild-type and FSM-resistant Dxr. Activity of
purified recombinant wild-type Dxr (A) and Dxr-S222T (B) enzymes with
increasing DOXP and FSM concentrations, as indicated, used to determine
inhibitory parameters (Table 3). Activity is measured in micromoles per min-
ute per milligram of enzyme. The data shown are representative of the results
of at least three independent experiments. The data points and error bars
represent mean	 standard error of the mean (SEM).
TABLE 2 IC50s and kinetic constants for recombinant wild-type dxr and dxr-S222T
a
Dxr allele
IC50 (mean [95% CI]) (nM) Vmax (mean [SEM])
(mol/min/mg of enzyme) Km (mean [SEM]) (M)Overall FR900098
dxr wt 34 (27–41) 24 (21–29) 12	 0.4 150	 23
dxr-S222T 1,100 (600–1,800) 890 (560–1,400) 11	 0.5 1,000	 270
a Data are from at least three independent experiments. Representative curves shown in Fig. 3A.
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nM [95% CI, 25 to 178 nM] and 460 nM [95% CI, 220 to 970 nM]
for BW25113 bamBtolC and BW25113 bamBtolC-dxr-
S222T, respectively; t test, P 0.005) (Fig. 6C and Table 4). These
data strongly indicate that FR900098, released from the prodrug,
binds to and inhibits Dxr in a manner similar to that of FSM.
These data confirm the utility of our system to establish the mech-
anisms of action of FSM analogs, such as FR900098, and prodrugs
requiring intracellular activation to release inhibitors of Dxr.
DISCUSSION
The non-mevalonate MEP pathway for isoprenoid biosynthesis is
a promising antimicrobial target, since this pathway is well vali-
dated and essential in a number of human pathogens but absent in
humans. In this work, we identified and characterized a novel
mutation (S222T) in the E. coli deoxyxylulose phosphate reduc-
toisomerase (Dxr), which confers resistance to the antimalarial
and antibacterial agent fosmidomycin (FSM). FSM, a phosphonic
acid antimicrobial, is the canonical MEP pathway inhibitor and
highlights the promise of new agents that target the MEP pathway.
While FSM is safe and well tolerated, it is also rapidly cleared (24,
25), and its biological spectrum of activity is limited due to cellular
exclusion in many organisms, including M. tuberculosis and T.
gondii (10, 29). Many attempts to modify FSM in the hopes of
improving efficacy against the enzyme or the organism have been
disappointing (32, 33, 35, 50, 51). Our studies provide definitive
evidence that the primary intracellular target of FSM is Dxr. In
addition, these studies establish and validate a novel system for
confirming the mechanisms of action of Dxr active-site inhibitors
and their prodrugs.
Dxr catalyzes the isomerization and NADPH-mediated reduc-
tion of DOXP to MEP, and this reaction is potently inhibited by
FSM in vitro. Unexpectedly, metabolic profiling has demonstrated
that MEP levels are relatively unchanged in FSM-treated E. coli
and P. falciparum malarial parasites, which suggests that the
downstream MEP-utilizing enzyme IspD represents a second in-
tracellular target (20). For this reason, we sought to identify point
mutations in either dxr or ispD that would confer FSM resistance.
We screened a library with 8,000 ispD mutants, which repre-
sented comprehensive mutagenesis of the small ispD locus (711
bp). Our efforts failed to identify any ispD alleles that conferred
resistance. In contrast, we were readily able to identify FSM-resis-
tant variants of dxr, with as much as 0.35% of our library confer-
ring resistance. This observation strongly suggests that Dxr
directly interacts with FSM within the cell. The effects of fosmido-
mycin on steady-state MEP levels, on the other hand, are likely to
be the result of indirect inhibition of IspD, although we cannot
rule out the possibility that mutations in ispD that confer FSM
resistance may also be incompatible with IspD activity and E. coli
survival.
The structural basis of FSM binding to Dxr has been well de-
scribed in multiple studies (36–38). The phosphonate moiety of
FSM, and presumably the phosphate moiety of the DOXP sub-
strate, are anchored by hydrogen bonding to four amino acids in
the Dxr active site: Ser186, Ser222, Asn227, and Lys228 (Fig. 2C).
Threonine, in place of serine, at position 222 is expected to pro-
trude into the substrate/FSM binding pocket and disrupt at least
one, if not multiple, hydrogen-bonding interactions. Consistent
with this prediction, the Dxr-S222T variant confers FSM resis-
tance in vitro and in vivo, and, in a similar manner, also requires
higher DOXP concentrations for effective catalysis. Surprisingly,
E. coli strains that solely express the Dxr-S222T variant are viable
and do not exhibit a substantial growth defect under laboratory
growth conditions, even though Dxr is essential for bacterial
growth and catalyzes a rate-limiting step in the MEP pathway.
Since a single point mutation confers resistance, and resistance
does not come with an apparent fitness disadvantage, the genetic
barrier to FSM resistance may be quite low. The development of
FSM resistance will require careful monitoring during clinical
treatment with FSM or related agents. The S222T variant therefore
represents a potential genetic biomarker of resistance to active-
site inhibitors of Dxr.
FSM is small and not easily modified without reducing po-
tency. These limitations have led to substantial efforts to develop
more cell-permeable analogs of FSM or its highly related analog
FR900098 (30–35). Because many FSM derivatives are prodrugs
that require intracellular activation, it is often impossible to test
the efficacy of these compounds directly on the Dxr target enzyme
in vitro. As a tool to confirm this intracellular target, we have
validated the S222T mutant strain using a cell-permeable prodrug
of the FSM analog FR900098 (D. J. Meyers et al., unpublished
data). As seen with fosmidomycin, the S222T mutation confers
35-fold resistance to FR900098 in vitro and 5.5-fold resistance in
vivo (Tables 2 and 4; see also Fig. S4 and S6 in the supplemental
material). We observed a very similar increase in the EC50 of a
novel FR900098 prodrug. Our results confirm that Dxr is the in-
tracellular target for this compound following FR900098 release
from the prodrug. In addition, these studies support the use of this
prodrug approach in antibacterial strategies to address (i) the
poor pharmacokinetics of FSM and analogs and/or (ii) the devel-
opment of resistance to this compound class through mutation of
FIG 5 Dxr-S222T supports bacterial growth and confers FSM resistance as the
sole cellular Dxr allele. The growth (A) and FSM sensitivity (B) of E. coli strain
MG1655, in which the native dxr locus has been replaced with either a wild-
type () or S222T (Œ) allele, are shown. The FSM sensitivity data are normal-
ized to growth in the absence of treatment. The data shown are representative
of the results of at least three independent experiments. The data points and
error bars represent mean	 standard error of the mean (SEM).
TABLE 3 Inhibitory kinetics of recombinant wild-type and S222T Dxra
Dxr variant
Mean	 SEM for:
Km (M) Vmax (mol/
min/mg of enzyme)
Ki (nM)
Dxr-wt 180	 29 13	 2.2 11	 0.9
Dxr-S222T 900	 210 11	 0.6 730	 14
a Data are from at least three independent experiments. Representative curves shown in
Fig. 4.
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active uptake via GlpT. Finally, our results underscore the value of
the S222T mutant strain for use in future drug discovery efforts as
we seek to improve prodrug scaffolds for optimal cellular uptake
and retention in bacteria or in intracellular pathogens, which
demonstrate natural resistance to FSM as a consequence of poor
uptake.
New antimalarial agents are in great demand due to wide-
spread resistance to former first-line agents and emerging resis-
tance to the newer artemisinin-based therapies. Within countries
that are endemic for malaria, the disease affects very high-risk
patient groups, specifically young infants and pregnant women. In
addition, many individuals require multiple courses of treatment
per year. For these reasons, new antimalarial therapies must be
exceptionally safe. Development efforts targeting the MEP path-
way aim to generate nontoxic compounds through the inhibition
of a target that is not present in humans. Since prodrugs are not
expected to exert inhibitory activity directly against the target and
are therefore not easily tested biochemically, compound develop-
ment may veer off target during development, thus eliminating
the parasite selectivity and safety advantages. Our FSM-resistant
E. coli strains are isogenic with wild-type bacteria, with the excep-
tion of a single amino acid change in a single protein, and bacterial
growth inhibition is straightforward to assay. We expect that these
strains will be of great utility in confirming the mechanism of
action in future efforts to develop inhibitors targeting the sub-
strate-binding pocket of Dxr for antibacterial, antitubercular, and
antimalarial therapies.
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